{"id":322,"date":"2014-07-02T07:11:43","date_gmt":"2014-07-02T11:11:43","guid":{"rendered":"http:\/\/blogs.shu.edu\/cancer\/?p=322"},"modified":"2021-07-02T08:52:00","modified_gmt":"2021-07-02T12:52:00","slug":"bi-specific-antibodies-matchmaking-cancer-and-t-cells","status":"publish","type":"post","link":"http:\/\/blogs.shu.edu\/cancer\/2014\/07\/02\/bi-specific-antibodies-matchmaking-cancer-and-t-cells\/","title":{"rendered":"Bi-specific antibodies – matchmaking cancer and T-cells"},"content":{"rendered":"

Amgen reported encouraging data from a 189 patient phase 2 trial at this year’s ASCO meeting on blinatumomab in patients with Philadelphia Chromosome (9,22 translocation) negative\u00a0relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL) \u00a0– see \u00a0http:\/\/ecancer.org\/conference\/514-asco-2014\/video\/2913\/blinatumomab-shown-to-be-beneficial-in-relapsed-refractory-b-precursor-acute-lymphoblastic-leukaemia.php<\/a>.<\/span><\/p>\n

Amgen’s BiTE technology generates bi-specific antibodies designed to bring T-cells in proximity with cancer cells. \u00a0In the case of blinatumumab, one variable region of the MAb targets CD3, a T-cell antigen required for T-cell activation, and the other targets CD19, which is expressed on the malignant B-cells – see diagram<\/a>. \u00a0The antibody brings the T cells and B cells in close proximity so that the T cells can engage and destroy the cancer, without the need for tumor associated antigen (TAA) processing and MHC Class I TAA\u00a0recognition.<\/p>\n

\"Bite2\"<\/a><\/p>\n

\"Bite3\"<\/a><\/p>\n

\"Bite4\"<\/a><\/p>\n

Fifty percent of patients with ALL are cured, by chemotherapy. \u00a0The remainder will die within 2 years unless bone marrow transplant is performed. \u00a0In the Phase 2 trial, 43% of patients that failed front-line chemotherapy had complete remission within 2 cycles. This therapy can extend the time required for BMT, without the need for additional toxic chemotherapy. \u00a0Finding appropriate BMT donors is not easy, so, blinatumumab can serve as a less toxic “bridge” to BMT. \u00a0Self-limited neurologic toxicity has been observed with blinatumumab, in a addition to cytokine release syndrome.<\/p>\n

Today, Amgen reported that it received Breakthrough Therapy Designation<\/a> from the FDA. \u00a0The FDA states that Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for Breakthrough Therapy Designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. A Breakthrough Therapy Designation conveys all of the fast-track program features, more intensive FDA guidance on an efficient drug development program, an organizational commitment involving senior managers, and eligibility for rolling review and priority review.<\/span><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Amgen reported encouraging data from a 189 patient phase 2 trial at this year’s ASCO meeting on blinatumomab in patients with Philadelphia Chromosome (9,22 translocation) negative\u00a0relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL) \u00a0– see \u00a0http:\/\/ecancer.org\/conference\/514-asco-2014\/video\/2913\/blinatumomab-shown-to-be-beneficial-in-relapsed-refractory-b-precursor-acute-lymphoblastic-leukaemia.php.<\/p>\n","protected":false},"author":2252,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[27,6,31],"tags":[182,1988,1989,181,184,183],"class_list":["post-322","post","type-post","status-publish","format-standard","hentry","category-antibodies-conjugates","category-immunology-immunotherapy","category-traditional-chemotherapy","tag-all","tag-blinatumomab","tag-blincyto","tag-breakthrough-therapy-dsignation","tag-cd19","tag-cd3"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/users\/2252"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/comments?post=322"}],"version-history":[{"count":4,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/322\/revisions"}],"predecessor-version":[{"id":4643,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/322\/revisions\/4643"}],"wp:attachment":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/media?parent=322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/categories?post=322"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/tags?post=322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}